PMS-RAMIPRIL CAPSULE
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
14-06-2018
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
RAMIPRIL
Dostopno od:
PHARMASCIENCE INC
Koda artikla:
C09AA05
INN (mednarodno ime):
RAMIPRIL
Odmerek:
5MG
Farmacevtska oblika:
CAPSULE
Sestava:
RAMIPRIL 5MG
Pot uporabe:
ORAL
Enote v paketu:
30/100/500
Tip zastaranja:
Prescription
Terapevtsko območje:
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Povzetek izdelek:
Active ingredient group (AIG) number: 0122858003; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2009-09-25
Lastnosti izdelka
PRODUCT MONOGRAPH
PR
PMS-RAMIPRIL
Ramipril Capsules, BP
1.25 mg, 2.5 mg, 5 mg, 10 mg and 15 mg
Angiotensin Converting Enzyme Inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave. Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
DATE OF REVISION: JUNE 14, 2018
Submission Control No: 216557
_pms-RAMIPRIL Product Monograph _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATION AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
................................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
..........................................................................................................26
DETAILED PHARMACOLOGY
.........
Preberite celoten dokument
